Abstract:
본 발명은 혈관신생 억제 활성을 갖는 펩타이드 및 이의 용도에 관한 것으로서, 보다 구체적으로는 혈관신생 억제 활성이 우수한 아미노산 서열을 포함하는 혈관신생 억제용 펩타이드, 상기 펩타이드를 포함하는 혈관신생 억제용 조성물, 상기 조성물을 포함하는 혈관신생 억제용 약제 및 상기 펩타이드를 이용한 혈관신생 억제 방법에 관한 것이다. 본 발명에 따른 아미노산 서열을 포함하는 혈관신생 억제용 펩타이드는 혈관내피세포의 세포 부착, 세포 이동 및 맥관 형성을 억제하는 활성이 우수할 뿐만 아니라 in vivo 혈관 신생을 억제하는 활성이 우수하고, 암 세포 증식 및 이동을 억제하는 활성이 우수하여 혈관신생이 비정상적으로 조절되어 야기되는 암을 포함하는 다양한 질환의 치료제로 유용하게 사용될 수 있는 효과가 있다.
Abstract:
PURPOSE: A method for screening a ROCK inhibitor is provided to easily and quickly screen a ROCK inhibitor without cytotoxicity. CONSTITUTION: A method for screening a ROCK(Rho-associated protein kinase) inhibitor comprises: a step of contacting a sample with stem cells; a step of culturing the stem cells in a medium; and a step of identifying stem cell differentiation. The stem cells are mesenchymal stem cells derived from adipose, bone marrow, peripheral blood, or umbilical cord blood. The method further comprises a step of bringing the sample into contact with cells, a step of culturing the cells, and a step of identifying toxicity of the sample.
Abstract:
PURPOSE: A peptide inhibiting angiogenesis activity and use thereof are provided to control in vivo vascularization, cancer cell adhesion, and angiogenesis of blood vessel endothelial cell, thereby being useful as therapeutic agents for various diseases. CONSTITUTION: A peptide inhibiting angiogenesis activity includes one amino acid sequence selected from amino acid sequences which are represented sequence number 1[SEQ ID NO:1]-sequence number 4. The peptide including the amino acid sequences represented by sequence 1 and 2 is originated from kringle domain of tissue-type plasmininogen activator. The peptide including the amino acid sequences marked as sequence number 3 and 4 is originated from the kringle domain of urokinase. The peptide controls cell proliferation of blood vessel endothelial cell, cell locomotion, and angiogenesis. The peptide also controls cancer cell proliferation and cell locomotion, thereby controlling in vivo vascularization.
Abstract:
A non-glycosylated recombinant protein comprising kringle domains 1 and 2 is provided to inhibit angiogenesis by inhibiting growth and mobility of vascular endothelial cells, and improve preparation yield of recombinant protein by removing a refolding step through eukaryotic cell expression system. A non-glycosylated recombinant protein comprises kringle domains 1 and 2 derived from human tissue type plasminogen activation factor(t-PA), in which 117 and 184 amino acids of t-PA are substituted from asparagine to glutamine, and has the amino acid sequence of SEQ ID NO:4. A gene encoding the non-glycosylated recombinant protein has the nucleotide sequence of SEQ ID NO:5. A Pichia pastoris(KCTC 11036BP) expresses the non-glycosylated recombinant protein comprising kringle domains 1 and 2.
Abstract translation:提供了包含三环结构域1和2的非糖基化重组蛋白,通过抑制血管内皮细胞的生长和迁移性来抑制血管生成,并通过通过真核细胞表达系统去除重折叠步骤来提高重组蛋白的制备产率。 非糖基化重组蛋白包含衍生自人组织型纤溶酶原激活因子(t-PA)的三环结构域1和2,其中t-PA的117和184个氨基酸被天冬酰胺取代为谷氨酰胺,并且具有氨基酸序列 的SEQ ID NO:4。 编码非糖基化重组蛋白的基因具有SEQ ID NO:5的核苷酸序列。 巴斯德毕赤酵母(KCTC 11036BP)表达包含三环结构域1和2的非糖基化重组蛋白。
Abstract:
A method for preparing a non-glycosylated recombinant protein is provided to obtain the recombinant protein easily with high yield without a refolding step using an eukaryotic expression system. A recombinant protein prepared by the method is provided to inhibit proliferation and movement of endothelial cells, thereby being very useful as an angiogenesis inhibitor. A method for preparing a non-glycosylated recombinant protein consisting of a kringle domain 1 and a kringle domain 2 comprises the steps of: (a) culturing Pichia pastoris(deposition no. KCTC 11038BP) which includes an amino acid sequence described as SEQ ID : NO. 4, has the angiogenesis inhibitory activity and expresses the non-glycosylated recombinant protein; and (b) subjecting the culture material of the step(a) to ion chromatography using an FPLC(fast protein liquid chromatography) column to isolate and purify the recombinant protein. A pharmaceutical composition for inhibiting the angiogenesis comprises the non-glycosylated recombinant protein derived from Pichia sp. as an effective ingredient.
Abstract:
본 발명은 ROCK 저해제 스크리닝 방법에 관한 것으로서, 분석하고자 하는 시료를 줄기세포에 접촉시키고 배지에서 배양시킨 후, 일정 시간 이후 분화된 줄기세포를 형태 변화를 사진촬영 등을 통해 관찰하여 분화 활성을 확인하고, 추가적으로 시료의 세포 독성 또한 조사함으로서 종합적으로 세포에 적용할 수 있으며, 일반적인 ROCK 저해제 뿐만 아니라 선택적 ROCK 저해제까지도 효과적으로 선별해 낼 수 있는 간편한 세포-기반의 시스템을 제공한다. 따라서 본 발명을 통해 각종 질병에 광범위하게 사용될 수 있으며 세포 독성이 없는 ROCK 저해제를 보다 쉽고 빠르게 스크리닝하여 제공할 수 있다는 효과가 있다.
Abstract:
PURPOSE: A composition containing a peroxidasin inhibitor for suppressing angiogenesis is provided to effectively prevent or treat various diseases caused by abnormal regulation of angiogenesis. CONSTITUTION: A composition for suppressing angiogenesis contains a peroxidasin expression inhibitor or activation inhibitor as an active ingredient. A peroxidasin gene has a base sequence in sequence number 1. Peroxidasin protein has an amino acid sequence in sequence number 12. The inhibitor includes an antisense oligonucleotide, siRNA, an aptamer, or an antibody which is specific to peroxidasin.